1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C6E3B6899855A7A085256A80004F6897
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/top-5-best-practices-in-launching-blockbuster-drugs?opendocument
18
19opendocument
2052.90.49.108
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Launch Strategy and Structure

Top 5 Best Practices in Launching Blockbuster Drugs

DB Image

ID: 4101


Features:


Words: 1,330


Published: Pre-2016


Delivery Format: Online


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
This document contains five top practices in launching blockbuster drugs. The leading practices, managerial insights and benchmark metrics in this report are drawn from in-depth interviews with more than 24 executives at 12 leading pharmaceutical companies.
“Top Five Best Practices in Launching Blockbuster Drugs” includes a top practice from each of five functional areas identified through extensive research and interviews.

Industries Profiled:
Pharmaceutical


Companies Profiled:
Leading pharmaceutical companies

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.